13.24
-0.17(-1.27%)
Currency In USD
| Previous Close | 13.41 |
| Open | 13.67 |
| Day High | 14.35 |
| Day Low | 13.23 |
| 52-Week High | 69.97 |
| 52-Week Low | 13.07 |
| Volume | 417,573 |
| Average Volume | 399,720 |
| Market Cap | 169.31M |
| PE | 0.05 |
| EPS | 279.15 |
| Moving Average 50 Days | 15.7 |
| Moving Average 200 Days | 25.95 |
| Change | -0.17 |
Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia
GlobeNewswire Inc.
Mar 10, 2026 12:00 PM GMT
Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025 In post hoc analysis of the pivotal RESILIENT study, TONMYA produced rapid pain relief as early as Day 2 of treatment, with durable pain reduction and sign
Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
GlobeNewswire Inc.
Mar 09, 2026 8:30 PM GMT
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally wel
Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting
GlobeNewswire Inc.
Mar 09, 2026 8:30 PM GMT
TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain reduction in two Phase 3 trials and was generally we